Document:

License
        Agreement

       

      Between
        ParkerVision and ITT

       

      * CERTAIN
        INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
        WITH RESPECT TO THE OMITTED PORTIONS.

       

      This
        Agreement (“Agreement”)
        is
        entered into and made effective as of 2 May 2007 (the “Effective
        Date”)
        by and
        between ITT Corporation, an Indiana corporation with offices at 1919 West
        Cook
        Road, Fort Wayne, Indiana 46801 (“ITT”)[*];
        and
        ParkerVision, Inc., a Florida corporation with offices at 7915 Baymeadows
        Way,
        Suite 400, Jacksonville, Florida, 32256 (“ParkerVision”).
        

       

      Recitals

       

      WHEREAS,
        ParkerVision has developed and patented technology known as direct2power
        or d2p
        (d2p Technology, as defined hereafter), that was designed to address certain
        limitations in applying traditional approaches to RF transmit and power
        amplification, and

       

      WHEREAS,
        d2p Technology allows for the creation of [*],
        known
        as “RF Power Transmitters”, and 

       

      WHEREAS,
        ITT desires to license from ParkerVision, and ParkerVision desires to license
        to
        ITT, the d2p Technology, pursuant to the terms and conditions of this Agreement,
        and 

       

      WHEREAS,
        concurrently with entering into this Agreement, the parties are also entering
        into an Engineering Services Agreement pursuant to which ParkerVision will
        provide engineering services to ITT with respect to the development by ITT
        of
[*]
        pursuant
        to the terms and conditions set forth therein,

       

      NOW,
        THEREFORE, in consideration of the mutual premises and of the performance
        of the
        mutual covenants herein, the parties agree as follows:

       

      1.  DEFINITIONS

       

      1.1  “Confidential
        Information”
has
        the
        meaning set forth in Section 10.1.

       

      1.2  “d2p
        Technology”
means
        technology delivered by ParkerVision to ITT under the Engineering Services
        Agreement [*]
        that is
        designed to address certain limitations in applying traditional approaches
        to RF
        transmit and power amplification. d2p Technology generally consists of
[*].

       

      1.3  “Development
        Tools”
means
        the ParkerVision development tools described in Sections 3.1.4, 3.2.2 and
        3.3.2
        of the Statement of Work attached to the Engineering Services Agreement.
        

       

      1.4  [*] 

       

      
        
          
          

        

        
          
          

          
            

          

        

        
          
          

        

      

       

      1.5  “Government
        Channels”
means
        the channels of marketing, sale, lease to and/or procurement for U.S. and
        foreign military and/or government entities including federal, state and
        local
        government entities and further including the respective departments and
        agencies that fall under such government entities. For clarification purposes,
        such government entities, purchasing for both civilian and military purposes,
        shall include, without limitation, the Department of Homeland Security, the
        National Guard and Fire/Police Departments under the respective agencies
        noted
        above. 

       

      1.6  “Implementation
        Technology”
        means
        any
        technology for incorporating or embodying the d2p Technology into a
        semiconductor device, wireless system or product (but excluding any
        technology that is developed based on the d2p Technology or that
        requires knowledge of the d2P Technology, which shall
        be
        deemed to fall within the definition of Improvements to d2p
        Technology). 
        [*]

       

      1.7  “Improvements
        to d2p Technology”
means
        any modifications, enhancements and improvements to the d2p Technology, but
        in
        no event includes any Implementation Technology except as set forth in the
        definition of Implementation Technology. 

       

      1.8  “Intellectual
        Property Rights”
means
        patents, certificates of invention, utility models, design rights and similar
        invention rights, copyrights, trade secret rights, mask work rights, and
        any
        other intangible property or proprietary rights (other than trademarks, trade
        names, service marks and trade dress rights) recognized anywhere in the world
        under any state or national statute or treaty or common law right, including
        without limitation all applications and registrations with respect to any
        of the
        foregoing. 

       

      1.9  “ITT
        Field of Use”
means
        [*]
        systems
        that are specifically designed, developed and adapted to
        meet the specifications and standards unique to [*]
        (with
        regard to matters such as the physical and operational characteristics,
        manufacturing processes, materials, reliability, compatibility with
        logistics systems and the like).  ITT Field of Use shall include the
        marketing, sale, lease to and/or procurement of such [*]
        systems [*].  ITT
        Field of Use shall not include any [*]
        (i.e.,
        not specifically designed, developed and adapted to meet the
        specifications and standards unique to [*])
        [*]
        systems,
        irrespective of whether such [*]
        systems
        are marketed, sold, leased to and/or procured [*].

       

      1.10  “[*]”
means
        the [*]
        that is
        developed under the Engineering Services Agreement and the Statement of Work
        attached thereto and that is based on the d2p Technology.

       

      1.11  “Licensed
        Patents”
        means:

       

      1.11.1  the
        issued patents listed in Exhibit
        A
        hereto;

       

      1.11.2  all
        patent(s) that may issue to ParkerVision based upon the United States patent
        application(s) listed in Exhibit
        A
        hereto;

       

      
        
          
          

        

        
          2

          
            

          

        

        
          
          

        

      

       

      1.11.3  all
        patent(s) that may issue to ParkerVision based upon the international patent
        application(s) listed in Exhibit
        A
        hereto;

       

      1.11.4  [*]

       

      1.11.5  all
        continuations, divisionals, reissues, reexaminations, and substitutions
        (“Continuations”)
        that
        may issue from any of the foregoing based on the subject matter disclosed
        in any
        of the foregoing, provided that such Continuations have Patent Claims covering
        [*]
        within
        the ITT Field of Use (as the ITT Field of Use is defined on the Effective
        Date).

       

      1.12  “Licensed
        Process”
means
        any process or method claimed in any of the Licensed Patents.

       

      1.13  “Licensed
        Product”
means
        any product in the ITT Field of Use that is developed by ITT and that
        incorporates one or more [*].

       

      1.14  “Licensed
        Technology”
means
        the d2p Technology, Improvements to d2p Technology, and Implementation
        Technology, all to the extent owned by ParkerVision and delivered by
        ParkerVision to ITT under the Engineering Services Agreement.

       

      1.15  “Open
        License Terms”
means
        terms in any license for software which require, as a condition of use,
        modification and/or distribution of such software or other software incorporated
        into, incorporating, derived from or distributed with such software (a
“Work”),
        any
        of the following:

       

      (a)
        the
        making available of source code, object code, or design information regarding
        the Work;

       

      (b)
        the
        granting of permission for creating derivative works regarding the Work;
        or

       

      (c)
        the
        granting of a license to any party under any Intellectual Property Rights
        in or
        to the Work.

       

      By
        means
        of example and without limitation, the following licenses and distribution
        models have Open License Terms: the GNU General Public License (GPL), the
        GNU
        Lesser or Library GPL (LGPL), Mozilla Public License (MPL), or any similar
        open
        source, free software or community licenses.

       

      1.16  “ParkerVision
        Software”
means
        any software delivered by ParkerVision to ITT under the Engineering Services
        Agreement, including without limitation the [*]
        and any
        software included within the Development Tools.

       

      
        
          
          

        

        
          3

          
            

          

        

        
          
          

        

      

       

      1.17  “Patent
        Claim”
shall
        have the meaning given to such term under the applicable laws of a patent
        office
        or jurisdiction and, for purposes of clarification, refers to a portion of
        a
        patent or patent application that defines the scope of protection for an
        invention. 

       

      1.18  “Royalty
        Fiscal Year”
means
        each twelve (12) month period beginning January 1 and ending
        December 31 of a particular calendar year.

       

      1.19  “Sell”
means
        sell, lease or otherwise distribute except for (i) distribution without any
        payment received by ITT for the purpose of testing, qualifications, or
        packaging, and (ii) distribution of a limited quantity without payment received
        by ITT for the purpose of evaluation.

       

      1.20  “Sold”
shall
        mean the past tense of Sell.

       

      2.  GRANT
        OF LICENSES

       

      2.1  Licensed
        Patents and Licensed Technology.

       

      2.1.1  Grant.
        Subject
        to the terms and conditions of this Agreement, ParkerVision grants to ITT,
        during the term of this Agreement, a [*]
        license,
        under the Licensed Patents and any copyrights and trade secrets and mask
        work
        rights (recognized anywhere in the world under any state or national statute
        or
        treaty or common law right, including without limitation all applications
        and
        registrations with respect to any of the foregoing) in and to the Licensed
        Technology owned or licensable by ParkerVision (with no right to sublicense),
        to
        use, modify, reproduce [*]
        (except
        as set forth below) of the Licensed Technology in order to develop Licensed
        Products only in the ITT Field of Use; to make, have made, use, lease, sell,
        offer for sale, import, distribute, transfer and otherwise exploit Licensed
        Products only in the ITT Field of Use; and to practice any Licensed Process
        involved in the manufacture or use thereof. 

       

      2.1.2  Have
        Made Rights.
        ITT
        understands and acknowledges that the “have made” rights granted in Section
        2.1.1 extend only to Licensed Products that are made by a third party for
        the
        use, lease, sale, offer for sale and/or import by or on behalf of ITT and
        (A)
        for which the Licensed Product will be branded by ITT or (B) where (whether
        branded by ITT or not) both
        (i)
        the designs, specifications and working drawings for the manufacture of the
        Licensed Product to be manufactured by that third party are furnished primarily
        by ITT and (ii) such designs, specifications and working drawings are in
        sufficient detail that no material additional design work is required by
        the
        third party, other than adaptation to the production processes and standards
        normally used by that third party, provided such adaptation only changes
        the
        characteristics of such Licensed Products to an extent that is not
        material.
        Upon
        written request from ParkerVision, ITT shall promptly inform ParkerVision
        in
        writing whether and to what extent any manufacturer identified by ParkerVision
        is operating under the Licensed Patents pursuant to ITT's “have made” rights
        granted under Section 2.1.1.

       

      2.1.3  No
        Reverse Engineering.
        Notwithstanding the above, with respect to any software included in the Licensed
        Technology, ITT shall not (a) modify, translate, reverse engineer, decompile,
        disassemble or otherwise attempt (i) to defeat, avoid, bypass, remove,
        deactivate or otherwise circumvent any software protection mechanisms in
        such
        software, including without limitation any such mechanism used to restrict
        or
        control the functionality of such software, or (ii) to derive the source
        code or the underlying ideas, algorithms, structure or organization from
        such
        software; (b) alter, adapt, modify or translate such software in any way
        for any
        purpose, including without limitation error correction; or (c) distribute,
        rent,
        loan, lease, transfer or grant any rights in such software or modifications
        thereof in any form to any person or entity.

       

      
        
          
          

        

        
          4

          
            

          

        

        
          
          

        

      

       

      2.1.4  [*]

       

      2.2  No
        Other Licenses.
        Except
        as expressly set forth in this Section 2, no license or other right is granted
        herein by either party to the other party, directly or by implication, estoppel
        or otherwise, and no such license or other right will arise from the
        consummation of this Agreement or from any acts, statements or dealings leading
        to such consummation. 

       

      3.  MARKETING
        OBLIGATIONS

       

      3.1  ITT
        Commitment to and Investment in d2p Technology.
        In the
        event that ITT fails to institute and diligently continue a program (including
        the continued allocation by ITT of commercially reasonable budget and resources
        for such program) with respect to the development of a Licensed Product up
        to
        its first customer shipment, then the [*]
        unless
        ITT is able to cure such failure within [*]
        of
        notice from ParkerVision. ITT agrees to respond promptly to ParkerVision’s
        inquiries regarding such program and in sufficient reasonable detail to enable
        ParkerVision to reasonably verify that ITT has instituted and is diligently
        continuing such a program with respect to the development of a Licensed Product
        by ITT.

       

      3.2  Public
        Announcements of this Agreement.
        Within
        three (3) business days after the Effective Date of this Agreement, either
        party
        may issue the press release in Exhibit C. Otherwise, neither party shall
        make
        any public announcement about this Agreement without the prior, written consent
        of the other party, which consent shall not be unreasonably withheld or delayed.
        Notwithstanding the foregoing, either of the parties may at any time make
        announcements which are required by applicable law, regulatory bodies, or
        stock
        exchange or stock association rules, so long as such party so required to
        make
        the announcement, promptly upon learning of such requirement, notifies the
        other
        party of such requirement and discusses with the other party in good faith
        the
        exact wording of any such announcement. 

       

      4.  LICENSE
        FEES AND ROYALTIES

       

      4.1  Royalties.

       

      4.1.1  Royalty
        Structure.
        Until
        ITT has Sold at least [*]
        Licensed
        Product [*],
        ITT
        will in any event pay royalties at the rate of [*]
        per
        Licensed Product irrespective of whether such Licensed Product is Sold
[*].
        Thereafter, ITT will pay royalties with respect to each Licensed Product
        that is
        Sold [*]
        at the
        rate that is the lesser of (i) the royalty per Licensed Product under
[*]
        Royalty
        Schedule A in Exhibit B,
        or (ii)
        the royalty per Licensed Product under [*]
        Royalty
        Schedule B in Exhibit B. Licensed Products Sold by ITT [*]
        shall
        not, in any event, be included in determining (i) [*]
        that
        triggers [*]
        under
        Royalty Schedule A in Exhibit B, and (ii) [*]
        that
        trigger [*]
        under
        Royalty Schedule B in Exhibit B.

       

      
        
          
          

        

        
          5

          
            

          

        

        
          
          

        

      

       

      4.1.2  [*]

       

      4.2  [*]

       

      4.3  [*]

       

      4.4  [*]

       

      4.5  When
        Royalties Become Payable.
        Royalties shall be calculated and paid for each quarter of a Royalty Fiscal
        Year
        with respect to Licensed Products Sold during that quarter, less Licensed
        Products returned to ITT for which (i) ITT refunded the purchase price and
        (ii)
        a royalty was previously paid by ITT to ParkerVision. Royalties due by ITT
        for
        each quarter shall be paid to ParkerVision within [*]
        following the end of each quarter of a Royalty Fiscal Year and shall be
        accompanied by the reports described in Section 5 below. In no event will
        ITT be
        entitled to any refund of
        any
        royalties previously paid.

       

      4.6  Taxes.
        All
        payments by ITT shall be made free and clear of, and without reduction for,
        any
        and all taxes, including, without limitation, sales, use, property, license,
        value added, excise, franchise, income, withholding or similar taxes, other
        than
        such taxes which are imposed by the United States or any political subdivision
        thereof based on the net income of ParkerVision. Any such taxes which are
        otherwise imposed on payments to ParkerVision shall be the sole responsibility
        of ITT. ITT shall provide ParkerVision with official receipts issued by the
        appropriate taxing authority or such other evidence as is reasonably requested
        by ParkerVision to establish that such taxes have been paid.

       

      5.  REPORTS
        AND AUDIT

       

      5.1  Records
        and Royalty Reports.
        ITT
        shall keep accurate records of its operations respecting the sale, lease
        or
        other distribution of the Licensed Products by ITT to the extent necessary
        (i)
        for the royalties payable hereunder to be determined, or (ii) to inform
        ParkerVision of all Licensed Products sold, leased or otherwise distributed
        by
        ITT, including without limitation for testing, qualifications and evaluation
        purposes. Such records shall include, without limitation, records of the
        quantity of such Licensed Products. ITT shall prepare quarterly written reports
        of the same, disclosing the quantity of such Licensed Products sold, leased
        or
        otherwise distributed by ITT and showing the amount of royalties due for
        such
        quarter, and shall promptly submit such reports to ParkerVision within
[*]
        after
        the end of each quarter of a Royalty Fiscal Year.

       

      5.2  Audit.
        Upon at
        least [*]
        advance,
        written notice and no more frequently than once per calendar year, ParkerVision
        shall have the right, at its own expense, to examine such records through
        an
        independent representative during ordinary business hours to the extent
        reasonably necessary to confirm or correct such reports. Such inspections
        shall
        be made by a mutually agreed upon representative, which representative may
        furnish to ParkerVision only its conclusions as to the accuracy of such reports,
        as to any discrepancies therein, and as to any adjustment necessary to be
        made
        to provide for payment of the proper amount of royalties, but not any other
        information of ITT gleaned in the course of such audit. In the event that
        any
        examination by such mutually agreed upon representative reveals that ITT
        has
        underpaid royalties due to ParkerVision by [*]
        or more,
        then ITT shall reimburse ParkerVision for the reasonable cost of such audit.
        ITT
        shall further promptly pay to ParkerVision any additional royalties due after
        the receipt of written notice by ParkerVision of ITT’s underpayment. With
        respect to any underpayments more than [*]
        old, ITT
        agrees to pay interest on such underpayments at the lowest rate that ITT
        is
        currently paying, or has most recently paid, for a loan from a commercial
        bank
        as of the date the audit reveals such underpayment. All information disclosed
        under this Section 5.2 shall be deemed ITT Confidential Information and
        shall be used for the sole purpose of verifying proper reporting of Licensed
        Products and proper payment of royalties. For any audit under this Section
        5.2
        that is subject to U.S. federal security regulations, such mutually agreed
        upon
        representative shall comply with applicable regulations and shall obtain
        any
        required security clearance prior to conducting any such audit.

       

      
        
          
          

        

        
          6

          
            

          

        

        
          
          

        

      

       

      5.3  Maintenance
        of Records.
        ITT
        shall maintain all records relating to the sale, lease or other distribution
        of
        the Licensed Products during the term of this Agreement for a period of four
        (4)
        Royalty Fiscal Years after the applicable Royalty Fiscal Year, after which
        ITT
        shall have no obligation to maintain, and ParkerVision shall have no right
        to
        inspect, any such records relating to such applicable Royalty Fiscal
        Year.

       

      6.  [*]

       

               
        [*] 

       

      7.  [*]

       

               
        [*] 

       

      
        
          
          

        

        
          7

          
            

          

        

        
          
          

        

      

       

      8.  [*]

       

               
        [*]

       

       

      9.  PATENTS

       

      9.1  Current
        Patents.
        ParkerVision hereby represents that the issued patents and patent applications
        listed on Exhibit A include all issued patents and patent applications owned
        by
        ParkerVision as of the Effective Date that have Patent Claims covering the
        Licensed Technology. [*]

       

      9.2  [*]

       

      10.  CONFIDENTIAL
        INFORMATION

       

      10.1  “Confidential
        Information”
means,
        with respect to either party, any confidential business or technical
        information, including know-how, whether or not patentable or copyrightable,
        that the disclosing party identifies as confidential or proprietary at the
        time
        it is disclosed or delivered to the receiving party. The d2p Technology,
        the
        Licensed Technology and the contents of any Licensed Patents and patent
        applications listed in Exhibit A shall in any event be deemed the Confidential
        Information of ParkerVision. Further, any [*]
        shall be
        deemed the Confidential Information of the developing party and such party
        shall
        have no obligation to disclose such [*]
        to the
        other party.

       

      10.2  Exceptions.
        Confidential Information does not include any information that the receiving
        party can demonstrate by written records: (a) was known to the receiving
        party prior to its disclosure hereunder by the disclosing party; (b) is
        independently developed by the receiving party; (c) is or becomes publicly
        known through no wrongful act of the receiving party; (d) has been
        rightfully received from a third party whom the receiving party has reasonable
        grounds to believe is authorized to make such disclosure without restriction;
        or
        (e) has been approved for public release by the disclosing party’s prior
        written authorization. Each party may disclose any Confidential Information
        as
        required to be produced or disclosed pursuant to applicable law, regulation
        or
        court order, provided that the receiving party provides prompt advance notice
        thereof to enable the disclosing party to seek a protective order or otherwise
        prevent such disclosure. In addition, each party may disclose the existence
        and
        terms of this Agreement in confidence in connection with [*]
        or
[*],
        or to
        the extent required by law in connection with a public offering of such party’s
        securities pursuant to Section 3.2.

       

      10.3  Non-Disclosure
        and Non-Use.
        Each
        party will: (i) not use any Confidential Information of the other party except
        in the performance of the Engineering Services Agreement or as permitted
        by this
        Agreement; (ii) not disclose any such Confidential Information to any person
        or
        entity other than its own employees, consultants, subcontractors and customers
        of ITT that fall under the U.S. Federal Government who have a need to know
        and
        who have executed in advance of receiving such Confidential Information a
        suitable nondisclosure and restricted use agreement that comports with the
        applicable provisions of this Agreement; and (iii) use all reasonable efforts
        to
        keep such Confidential Information strictly confidential. Each party will
        use
        reasonable efforts to enforce such nondisclosure and restricted use
        agreements.

       

      
        
          
          

        

        
          8

          
            

          

        

        
          
          

        

      

       

      11.  PATENT
        MARKING

       

      ITT
        agrees to mark the documentation associated with the Licensed Products with
        the
        number(s) of the Licensed Patent(s) covering such Licensed Products and with
        “Patent Pending” (along with a listing of the relevant patent application
        numbers) if any patent applications relating to such Licensed Products are
        pending before the United States Patent and Trademark Office or the patent
        office of a foreign country, as applicable.

       

      12.  TERM

       

      Unless
        earlier terminated in accordance with the terms of this Agreement, this
        Agreement shall extend until [*].

       

      13.  TERMINATION

       

      13.1  Termination
        for Breach.
        At any
        time after the occurrence of an Event of Default, this Agreement may be
        terminated at the election of the Non-Defaulting Party, effective as of the
        date
        specified in a notice of termination provided to the Defaulting Party. As
        used
        herein, “Event
        of Default”
means
        one or more of the following events: if there should occur a material breach,
        default or noncompliance by one party (the “Defaulting
        Party”)
        of or
        with any term or condition hereof followed by written notice of such breach,
        default or noncompliance from the other party (the “Non-Defaulting
        Party”)
        and
        the failure of the Defaulting Party to remedy or correct such breach, default
        or
        noncompliance within [*]
        after
        receipt of such notice (the “Cure
        Period”).
        

       

      13.2  Termination
        if ITT discontinues Licensed Products after [*].
        Either
        party may terminate this Agreement upon written notice to the other party
        in the
        event that after [*],
        ITT has
        not Sold any Licensed Products in any consecutive [*]
        period
        following [*].
        [*] 

       

      13.3  Termination
        upon ITT Challenge to the Licensed Patents.
        ParkerVision may terminate this Agreement upon written notice to ITT in the
        event ITT leads or supports (other than as required by law or court order)
        any
        effort to challenge the validity, enforceability or scope of any Licensed
        Patent. In the event that ITT is a party to any claim, suit, action or other
        proceeding before a court or other government agency, in which ITT supports
        (other than as required by law or court order) a challenge to the validity,
        enforceability or scope of any Licensed Patent, ParkerVision shall be entitled
        to recover from ITT any and all costs and expenses, including reasonable
        attorneys’ fees and expenses of investigation and defense, incurred by
        ParkerVision in such claim, suit, action or other proceeding, and ITT will
        not
        be entitled to any refund of any royalties previously paid.

       

      
        
          
          

        

        
          9

          
            

          

        

        
          
          

        

      

       

      13.4  Effect
        of Termination or Expiration.
        

       

      13.4.1  Cease
        Use of Technology and Return Materials.
        In the
        event this Agreement is terminated by either party, then all licenses granted
        to
        ITT will automatically cease as of the date of termination, provided, however,
        that:

       

      13.4.1.1.  For
        a
        period of [*]
        after
        termination, and subject to the payment of royalties under Section 4, ITT
        shall
        have the right to Sell off any Licensed Products in inventory, except that
        ITT
        shall not have such rights to Sell off any Licensed Products in inventory
        in the
        event this Agreement is terminated by ParkerVision under Section 13.3;
        and

       

      13.4.1.2.  Upon
        termination or expiration of this Agreement and except as otherwise provided
        herein, each party may keep only one (1) copy of the technology, materials
        and
        information provided to it by the other party hereunder solely for archival
        purposes and shall return to the other party or destroy all other copies
        of the
        technology, materials and information provided to it by the other party
        hereunder, or any portion thereof, in its possession or control.  

       

      13.4.2  Payment
        of Royalties.
        Upon
        any expiration or termination becoming effective, ITT will, within [*]
        thereafter, pay all royalties and interest owed ParkerVision as of the date
        of
        such termination or expiration. 

       

      13.5  Survival
        of Certain Provisions.
        The
        provisions of Sections 2.1.3, 4, 5, 6, 10, 11, 13.3, 13.4, 14.2 and 15-17
        of
        this Agreement will survive any expiration or termination of this
        Agreement.

       

      14.  WARRANTIES
        

       

      14.1  Warranties.

       

      14.1.1  Warranties
        by ParkerVision.
        ParkerVision hereby represents and warrants to ITT that: (a) it has the full
        right, power and authority to enter into this Agreement and grant the licenses
        granted hereunder; (b) this Agreement is a valid and binding obligation of
        such
        party; and (c) it has obtained and shall maintain throughout the term of
        this
        Agreement all necessary licenses, authorizations, approvals and consents
        to
        enter into and perform its obligations hereunder in compliance with all
        applicable laws, rules and regulations. ParkerVision further represents and
        warrants that, as of the Effective Date, ParkerVision is not aware of and
        has
        not received any notice of any claim, by a third party, that the copyrights,
        patents, trade secrets, or other Intellectual Property Rights of any third
        party
        are infringed by the Licensed Technology. ParkerVision represents and warrants
        that the ParkerVision Software is not subject to Open License Terms. In the
        event of a breach of the preceding warranty against Open License Terms,
        ParkerVision will, at its sole expense, promptly (i) notify ITT of any affected
        portions of ParkerVision Software, and (ii) take all reasonable efforts to
        replace such affected portions of ParkerVision Software with software of
        equivalent functionality that is not subject to Open License Terms. For purposes
        of clarification, a claim alleging that ITT’s authorized use of the ParkerVision
        Software infringes any Open License Terms in the ParkerVision Software is
        an
        allegation of copyright infringement under Section 15 below.

       

      
        
          
          

        

        
          10

          
            

          

        

        
          
          

        

      

       

      14.1.2  Warranties
        by ITT.
        ITT
        hereby represents and warrants to ParkerVision that: (a) it has the full
        right,
        power and authority to enter into this Agreement and grant the licenses granted
        hereunder; (b) this Agreement is a valid and binding obligation of such party;
        and (c) it has obtained and shall maintain throughout the term of this Agreement
        all necessary licenses, authorizations, approvals and consents to enter into
        and
        perform its obligations hereunder in compliance with all applicable laws,
        rules
        and regulations. ITT
        represents and warrants that ITT shall not act in any manner that would require
        any ParkerVision Software to be licensed under Open License Terms. 

       

      14.2  Disclaimer
        of Other Warranties.
        EXCEPT
        AS SET FORTH IN SECTION 14.1, NEITHER PARTY MAKES ANY WARRANTIES TO THE OTHER,
        EITHER EXPRESS, IMPLIED OR STATUTORY, AND EACH PARTY HEREBY DISCLAIMS ANY
        AND
        ALL SUCH WARRANTIES, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF
        MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. Nothing
        contained in this Agreement shall be construed as (i) a warranty or
        representation by ParkerVision as to the validity and/or scope of any Licensed
        Patent; (ii) imposing upon ParkerVision any obligation to institute any suit
        or
        action for infringement of any Licensed Patent; or (iii) imposing on
        ParkerVision any obligation to file any patent application or to secure any
        patent or maintain any patent in force. 

       

      15.  INDEMNIFICATION

       

      15.1  ParkerVision
        Obligations.
        

       

      15.1.1  Intellectual
        Property Indemnity.
        Subject
        to prompt, written notification by ITT, cooperation by ITT and control of
        all
        litigation and/or settlement by ParkerVision, ParkerVision shall defend and
        indemnify ITT and hold ITT harmless from and against any third party claims
        brought against ITT alleging that any Licensed Technology incorporated into
        Licensed Products in the ITT Field of Use infringes or misappropriates any
        patent, copyright or trade secret of any third party. Each party agrees to
        notify the other promptly of any matters in respect to which the foregoing
        indemnity in this Section 15.1.1 may apply. If notified in writing of any
        action
        or claim for which ParkerVision is to provide the foregoing indemnity,
[*].
        Notwithstanding the foregoing, ParkerVision shall obtain ITT’s consent, which
        shall not be unreasonably withheld or delayed, if ITT is required to incur
        or
        admit liability as a result of such settlement by ParkerVision.

       

      15.1.2  Remedy
        in the Event of Prohibition of Use.
        If a
        preliminary or final judgment is, or is reasonably likely to be, entered
        against
        ITT’s use, sale, lease or distribution of a Licensed Product in the ITT Field
        of
        Use that incorporates any Licensed Technology, due to infringement of any
        third
        party patents, copyrights or trade secrets by the Licensed Technology, or
        if
        ParkerVision reasonably believes that the Licensed Technology may be found
        to
        infringe any third party patents, copyrights or trade secrets, then ParkerVision
        shall, at its sole discretion and expense, either (a) modify the Licensed
        Technology so that such technology becomes noninfringing, (b) substitute
        the
        Licensed Technology with other technology that is as close functionally as
        reasonably, commercially possible to the infringing technology, while still
        avoiding infringement and preserving all material functional aspects of the
        technology or (c) obtain a license to permit ITT to exercise the rights granted
        hereunder; provided, however, that in the event that ParkerVision is unable
        after its [*]
        to
        accomplish either (a), (b) or (c), then ITT agrees to cease any and all use,
        sale, lease and distribution of any Licensed Product that incorporates such
        Licensed Technology within [*]
        of
        receipt of notice from ParkerVision or such earlier time as may be required
        to
        comply with a court order. [*]
        In the
        event [*]
        then
        [*]
        this
        Agreement may not be terminated under Section 13.2 for ITT’s failure to Sell
        Licensed Products. For a period of [*]
        after
        the receipt of such notice by ITT, the parties agree to use [*]
        to
        cooperate in formulating and implementing a strategy (including negotiating
        cooperatively to obtain a license or any other mutually acceptable strategy)
        that will enable ITT to exercise the rights granted hereunder without
        infringement of such third party patents, copyrights or trade secrets by
        the
        Licensed Technology.

       

      
        
          
          

        

        
          11

          
            

          

        

        
          
          

        

      

       

      15.2  Limitation
        of Indemnification Liability.
        In no
        event shall ParkerVision be liable under Section 15.1 for any infringement
        or
        misappropriation: (i) by any product or technology not provided and
        licensed by ParkerVision hereunder; or (ii) arising from a combination
        with, addition to, or modification of the Licensed Technology. In no event
        shall
        ParkerVision’s liability under Section 15.1 over the term of this Agreement,
including
        without limitation any damages, settlement or license fees paid to a third
        party
        pursuant to ParkerVision’s indemnification obligations to ITT under Section
        15.1, exceed
        [*].
        However, the foregoing limitation of liability in the previous sentence shall
        not apply with respect to [*].

       

      15.3  Sole
        Remedy.
        THIS
        SECTION 15 STATES THE SOLE AND EXCLUSIVE LIABILITY OF THE PARTIES FOR
        INFRINGEMENT OR ALLEGATIONS OF INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS
        OF
        THIRD PARTIES FOR ANY PRODUCT OR TECHNOLOGY PROVIDED HEREUNDER, AND IS IN
        LIEU
        OF ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY IN REGARD THERETO, INCLUDING
        BUT NOT LIMITED TO THE WARRANTY AGAINST INFRINGEMENT SPECIFIED IN THE UNIFORM
        COMMERCIAL CODE.

       

      16.  LIMITATION
        OF LIABILITY

       

      16.1  IN
        NO
        EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR LOST PROFITS OR ANY SPECIAL,
        INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES (EXCEPT TO THE EXTENT
        THAT SUCH LOST PROFITS OR SUCH DAMAGES CONSTITUTE THE MEASURE OF DIRECT DAMAGES
        UNDER THE RELEVANT INTELLECTUAL PROPERTY LAWS AND EXCEPT FOR A BREACH OF
        EITHER
        PARTY’S CONFIDENTIALITY OBLIGATIONS UNDER SECTION 10 OF THIS AGREEMENT), HOWEVER
        CAUSED AND ON ANY THEORY OF LIABILITY, ARISING IN ANY WAY IN CONNECTION WITH
        THIS AGREEMENT. THIS LIMITATION WILL APPLY EVEN IF SUCH PARTY HAS BEEN ADVISED
        OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL
        PURPOSE OF ANY LIMITED REMEDY.

       

      
        
          
          

        

        
          12

          
            

          

        

        
          
          

        

      

       

      16.2  IN
        NO
        EVENT WILL EITHER PARTY’S LIABILITY ARISING IN ANY WAY IN CONNECTION WITH THIS
        AGREEMENT (INCLUDING WITHOUT LIMITATION ANY DAMAGES, SETTLEMENT OR LICENSE
        FEES
        OWED BY PARKERVISION UNDER SECTION 15 OF THIS AGREEMENT) EXEED [*].
        HOWEVER, THE FOREGOING LIMITATION OF LIABILITY IN THIS SECTION 16.2 SHALL
        NOT
        APPLY WITH RESPECT TO (i) EITHER PARTY’S BREACH, OR EXCEEDING THE SCOPE, OF THE
        LICENSE RIGHTS GRANTED TO SUCH PARTY UNDER SECTIONS 2 AND 6 OF THIS AGREEMENT,
        AND (ii) EITHER PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS UNDER SECTION
        10 OF THIS AGREEMENT, AND (iii) [*].

       

      17.  GENERAL
        PROVISIONS

       

      17.1  Assignment.
        This
        Agreement may not be assigned in whole or in part by either
        party
        without the written consent of the other, which consent will not be unreasonably
        withheld, except that ITT or ParkerVision may assign this Agreement in
        connection with a merger, reorganization, change of control or sale of all
        or
        substantially all of its assets or business to which this Agreement
        relates.

       

      17.2  Notice.

       

      17.2.1  Unless
        otherwise changed by notice in writing from ITT to ParkerVision,
        ParkerVision shall serve notice upon ITT as follows:

       

      General
        Counsel

      [*]
        ITT
        Corporation

      1919
        West
        Cook Road

      Fort
        Wayne, Indiana 46801

       

      17.2.2  Unless
        otherwise changed by notice in writing from ParkerVision to ITT, ITT shall
        serve
        notice upon ParkerVision as follows:

       

      ParkerVision,
        Inc.

      7915
        Baymeadows Way, Suite 400

      Jacksonville,
        Florida, 32256

      

      With
        copy
        to: 

      

      CFO

      ParkerVision,
        Inc.

      7915
        Baymeadows Way, Suite 400

      Jacksonville,
        Florida, 32256

       

      
        
          
          

        

        
          13

          
            

          

        

        
          
          

        

      

       

      17.2.3  Notice
        shall be by regular or priority mail, recognized commercial overnight courier,
        hand delivery, facsimile transmission or electronic mail with proof of receipt,
        and shall be effective as of the date received.

       

      17.3  Severability.
        If any
        paragraph or provision of this Agreement shall be deemed void or invalid
        as a
        matter of law, the remaining paragraphs or provisions of this Agreement shall
        nevertheless remain in full force and effect.

       

      17.4  No
        Joint Venture, etc.
        Nothing
        herein shall be deemed to constitute ParkerVision and ITT as partners, joint
        venturers or otherwise associated in or with the business of the other. Neither
        party shall be liable for any debts, accounts, obligations or other liabilities
        of the other party. Neither party is authorized to incur any debts or other
        obligations of any kind on the part of or as agent for the other except as
        may
        be specifically authorized in writing.

       

      17.5  Waiver.
        No
        relaxation, forbearance, delay or negligence by any party hereto in enforcing
        any of the terms and conditions of this Agreement, or the granting of time
        by
        any party to another, shall operate as a waiver or prejudice, affect or restrict
        the rights, powers or remedies of any party hereto.

       

      17.6  Complete
        Agreement.
        This
        Agreement and the Exhibits attached hereto represent the full and complete
        agreement and understanding of the parties hereto with respect to the subject
        matter hereof. Any amendment thereof must be in writing and executed by the
        parties hereto. 

       

      17.7  Governing
        Law.
        All
        questions of law, rights, and remedies regarding any act, event or occurrence
        undertaken prior to or pursuant to this Agreement shall be governed by and
        construed in accordance with the laws of the State of New York, without regard
        to or application of choice of law rules or principles, and the United States.
        The
        parties agree that all proceedings, disputes and claims concerning the
        interpretation or the performance of this Agreement, including questions
        involving its existence, validity and duration shall be subject to the exclusive
        jurisdiction of federal courts in the State of New York, and the parties
        voluntarily subject themselves to the jurisdiction of such courts.
        

       

      17.8  Compliance
        with Export Control Laws. 
        Each party agrees to comply with all applicable export and reexport control
        laws
        and regulations, including the Export Administration Regulations ("EAR")
        maintained by the United States Department of Commerce.  Specifically, each
        party covenants that it shall not -- directly or indirectly -- sell, export,
        reexport, transfer, divert, or otherwise dispose of any software, source
        code,
        or technology (including products derived from or based on such technology)
        received from the other party under this Agreement to any country (or any
        individual national thereof) subject to antiterrorism controls or U.S. embargo,
        or to any other person, entity, or destination prohibited by the laws or
        regulations of the United States, without obtaining prior authorization from
        the
        competent government authorities as required by those laws and
        regulations. 

       

      
        
          
          

        

        
          14

          
            

          

        

        
          
          

        

      

       

      17.9  Multiple
        Counterparts.
        This
        Agreement may be executed in multiple counterparts, each of which will be
        considered an original and all of which together will constitute one agreement.
        This Agreement may be executed by the attachment of signature pages which
        have
        been previously executed.

       

      17.10   Remedies
        Cumulative.
        Except
        as expressly provided herein, all rights and remedies enumerated in this
        Agreement will be cumulative and none will exclude any other right or remedy
        permitted herein or by law or in equity.

       

      17.11   Headings.
        The
        headings contained in this Agreement are inserted for convenience of reference
        only and are not intended to be a part of or to affect the meaning or
        interpretation of this Agreement.

       

      17.12  Force
        Majeure.
        No
        party shall be responsible or liable to another party for nonperformance
        or
        delay in performance of any terms or conditions of this Agreement due to
        acts or
        occurrences beyond the reasonable control of the nonperforming or delayed
        party,
        including but not limited to, acts of God, acts of government, wars, riots,
        strikes or other labor disputes, fires and floods, provided the nonperforming
        or
        delayed party provides to the other party written notice of the existence
        and
        the reason for such nonperformance or delay. Notwithstanding the foregoing,
        the
        other party may terminate this agreement if such nonperformance or delay
        extends
        for a period greater than ninety (90) days. 

      

      IN
        WITNESS WHEREOF, the parties have executed this Agreement through their duly
        authorized representatives as set forth below:

       

      
        	ITT
                Corporation	 	 	ParkerVision,
                Inc.
	 	 	 	 
	Signature:
                /s/ 	 	 	Signature:
                /s/ 
	
                

              	 	 	
                

              
	
                Printed
                  Name: [*]

                 

                Title:
                  [*]

              	 	 	
                Printed
                  Name: [*]

                 

                Title:
                  [*]

              

      

       

      
        
          
          

        

        
          15Unassociated Document

    

    SUNESIS
      PHARMACEUTICALS, INC.

    2005
      EQUITY INCENTIVE AWARD PLAN

    (Amended
      and Restated June 27, 2007)

    

    ARTICLE
      1

    PURPOSE

     

    1.1  General.
      The
      purpose of the Sunesis Pharmaceuticals, Inc. 2005 Equity Incentive Award Plan
      (the “Plan”)
      is to
      promote the success and enhance the value of Sunesis Pharmaceuticals, Inc.
      (the
“Company”)
      by
      linking the personal interests of the members of the Board, employees,
      consultants, officers, and executives of the Company and any Subsidiary, to
      those of Company stockholders and by providing such individuals with an
      incentive for outstanding performance to generate superior returns to Company
      stockholders. The Plan is further intended to provide flexibility to the Company
      in its ability to motivate, attract, and retain the services of members of
      the
      Board, employees, consultants, officers, and executives of the Company upon
      whose judgment, interest, and special effort the successful conduct of the
      Company’s operation is largely dependent. 

     

    ARTICLE
      2

    DEFINITIONS
      AND CONSTRUCTION

     

    2.1  Definitions.
      The
      following words and phrases shall have the following meanings:

     

    (a)  “Award”
means
      an Option, a Restricted Stock award, a Stock Appreciation Right award, a
      Performance Share award, a Dividend Equivalents award, a Stock Payment award,
      a
      Restricted Stock Unit award, or a Performance-Based Award granted to a
      Participant pursuant to the Plan.

     

    (b)  “Award
      Agreement”
means
      any written agreement, contract, or other instrument or document evidencing
      an
      Award.

     

    (c)  “Board”
means
      the Board of Directors of the Company.

     

    (d)  “Cause”
      includes one or more of the following: (i) the commission of an act of fraud,
      embezzlement or dishonesty by a Participant that has a material adverse impact
      on the Company or any successor or parent or Subsidiary thereof; (ii) a
      conviction of, or plea of “guilty” or “no contest” to, a felony by a
      Participant; (iii) any unauthorized use or disclosure by a Participant of
      confidential information or trade secrets of the Company or any successor or
      parent or Subsidiary thereof that has a material adverse impact on any such
      entity or (iv) any other intentional misconduct by a Participant that has a
      material adverse impact on the Company or any successor or parent or Subsidiary
      thereof. However, if the term or concept of “Cause” has been defined in an
      agreement between a Participant and the Company or any successor or parent
      or
      Subsidiary thereof, then “Cause” shall have the definition set forth in such
      agreement. The foregoing definition shall not in any way preclude or restrict
      the right of the Company or any successor or parent or Subsidiary thereof to
      discharge or dismiss any Participant in the service of such entity for any
      other
      acts or omissions, but such other acts or omissions shall not be deemed, for
      purposes of this Plan, to constitute grounds for termination for
      Cause.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    (e)  “Change
      of Control”
means
      and includes each of the following:

     

    (1)
       the
      acquisition, directly or indirectly, by any “person” or “group” (as those terms
      are defined in Sections 3(a)(9), 13(d) and 14(d) of the Exchange Act and the
      rules thereunder) of “beneficial ownership” (as determined pursuant to
      Rule 13d-3 under the Exchange Act) of securities entitled to vote generally
      in the election of directors (“voting securities”) of the Company that represent
      50% or more of the combined voting power of the Company’s then outstanding
      voting securities, other than:

     

    (A)
       an
      acquisition by a trustee or other fiduciary holding securities under any
      employee benefit plan (or related trust) sponsored or maintained by the Company
      or any person controlled by the Company or by any employee benefit plan (or
      related trust) sponsored or maintained by the Company or any person controlled
      by the Company, or 

     

    (B)
       an
      acquisition of voting securities by the Company or a corporation owned, directly
      or indirectly by the stockholders of the Company in substantially the same
      proportions as their ownership of the stock of the Company;

     

    Notwithstanding
      the foregoing, the following event shall not constitute an “acquisition” by any
      person or group for purposes of this subsection (e): an acquisition of the
      Company’s securities by the Company that causes the Company’s voting securities
      beneficially owned by a person or group to represent 50% or more of the combined
      voting power of the Company’s then outstanding voting securities; provided,
      however,
      that if
      a person or group shall become the beneficial owner of 50% or more of the
      combined voting power of the Company’s then outstanding voting securities by
      reason of share acquisitions by the Company as described above and shall, after
      such share acquisitions by the Company, become the beneficial owner of any
      additional voting securities of the Company, then such acquisition shall
      constitute a Change of Control; or 

     

    (2)
       during
      any period of two consecutive years, individuals who, at the beginning of such
      period, constitute the Board together with any new director(s) (other than
      a
      director designated by a person who shall have entered into an agreement with
      the Company to effect a transaction described in clauses (1) or (3) of
      this subsection (e)) whose election by the Board or nomination for election
      by
      the Company’s stockholders was approved by a vote of at least two-thirds of the
      directors then still in office who either were directors at the beginning of
      the
      two year period or whose election or nomination for election was previously
      so
      approved, cease for any reason to constitute a majority thereof; or

     

    (3)
       the
      consummation by the Company (whether directly involving the Company or
      indirectly involving the Company through one or more intermediaries) of
      (x) a merger, consolidation, reorganization, or business combination or
      (y) a sale or other disposition of all or substantially all of the
      Company’s assets or (z) the acquisition of assets or stock of another
      entity, in each case other than a transaction:

     

    (A)
       which
      results in the Company’s voting securities outstanding immediately before the
      transaction continuing to represent (either by remaining outstanding or by
      being
      converted into voting securities of the Company or the person that, as a result
      of the transaction, controls, directly or indirectly, the Company or owns,
      directly or indirectly, all or substantially all of the Company’s assets or
      otherwise succeeds to the business of the Company (the Company or such person,
      the “Successor
      Entity”))
      directly or indirectly, at least a majority of the combined voting power of
      the
      Successor Entity’s outstanding voting securities immediately after the
      transaction, and 

     

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

     

    (B)
       after
      which no person or group beneficially owns voting securities representing 50%
      or
      more of the combined voting power of the Successor Entity; provided,
      however,
      that no
      person or group shall be treated for purposes of this clause (B) as
      beneficially owning 50% or more of combined voting power of the Successor Entity
      solely as a result of the voting power held in the Company prior to the
      consummation of the transaction; or 

     

    (4)
       the
      Company’s stockholders approve a liquidation or dissolution of the Company.

     

    The
      Committee shall have full and final authority, which shall be exercised in
      its
      discretion, to determine conclusively whether a Change of Control of the Company
      has occurred pursuant to the above definition, and the date of the occurrence
      of
      such Change of Control and any incidental matters relating thereto.

     

    (f)  “Code”
means
      the Internal Revenue Code of 1986, as amended.

     

    (g)  “Committee”
means
      the committee of the Board described in Article 12. 

     

    (h)  “Covered
      Employee”
means
      an Employee who is, or could be, a “covered employee” within the meaning of
      Section 162(m) of the Code.

     

    (i)  “Disability” means,
      for purposes of this Plan, that the Participant qualifies to receive long-term
      disability payments under the Company’s long-term disability insurance program,
      as it may be amended from time to time.

     

    (j)  “Dividend
      Equivalents”
means
      a
      right granted to a Participant pursuant to Article 8 to receive the equivalent
      value (in cash or Stock) of dividends paid on Stock.

     

    (k)  “Employee”
means
      any officer or other employee (as defined in accordance with Section 3401(c)
      of
      the Code) of the Company or any Subsidiary.

     

    (l)  “Exchange
      Act”
means
      the Securities Exchange Act of 1934, as amended.

     

    (m)  “Fair
      Market Value”
shall
      mean, as of any date, the value of Stock determined as follows:

     

    (1)  If
      the
      Stock is listed on any established stock exchange or a national market system,
      its Fair Market Value shall be the closing sales price for such stock (or the
      closing bid, if no sales were reported) as quoted on such exchange or system
      for
      such date, or if no bids or sales were reported for such date, then the closing
      sales price (or the closing bid, if no sales were reported) on the trading
      date
      immediately prior to such date during which a bid or sale occurred, in ease
      case, as reported in The
      Wall Street Journal
      or such
      other source as the Committee deems reliable;

     

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

     

    (2)  If
      the
      Stock is regularly quoted by a recognized securities dealer but selling prices
      are not reported, its Fair Market Value shall be the mean of the closing bid
      and
      asked prices for the Stock on the date prior to the date of determination as
      reported in The
      Wall Street Journal
      or such
      other source as the Committee deems reliable; or

     

    (3)  In
      the
      absence of an established market for the Stock, the Fair Market Value thereof
      shall be determined in good faith by the Committee.

     

    (n)  “Good
      Reason”
means
      a
      Participant’s voluntary resignation following any one or more of the following
      that is effected without the Participant’s written consent: (i) a change in his
      or her position following the Change of Control that materially reduces his
      or
      her duties or responsibilities, (ii) a reduction in his or her base salary
      following a Change of Control, unless the base salaries of all similarly
      situated individuals are similarly reduced, or (iii) a relocation of such
      Participant’s place of employment following a Change of Control by more than
      fifty (50) miles from such Participant’s place of employment prior to a Change
      of Control. However, if the term or concept of “Good Reason” has been defined in
      an agreement between a Participant and the Company or any successor or parent
      or
      Subsidiary thereof, then “Good Reason” shall have the definition set forth in
      such agreement. 

     

    (o)  “Incentive
      Stock Option”
means
      an Option that is intended to meet the requirements of Section 422 of the Code
      or any successor provision thereto.

     

    (p)  “Non-Employee
      Director”
means
      a
      member of the Board who qualifies as a “Non-Employee Director” as defined in
      Rule 16b-3(b)(3) of the Exchange Act, or any successor definition adopted by
      the
      Board.

     

    (q)  “Non-Qualified
      Stock Option”
means
      an Option that is not intended to be an Incentive Stock Option.

     

    (r)  “Option”
means
      a
      right granted to a Participant pursuant to Article 5 of the Plan to purchase
      a
      specified number of shares of Stock at a specified price during specified time
      periods. An Option may be either an Incentive Stock Option or a Non-Qualified
      Stock Option.

     

    (s)  “Participant”
means
      a
      person who, as a member of the Board, consultant to the Company or any
      Subsidiary or Employee, has been granted an Award pursuant to the
      Plan.

     

    (t)  “Performance-Based
      Award”
means
      an Award granted to selected Covered Employees pursuant to Articles 6 and 8,
      but
      which is subject to the terms and conditions set forth in Article 9. All
      Performance-Based Awards are intended to qualify as Qualified Performance-Based
      Compensation.

     

    (u)  “Performance
      Criteria”
means
      the criteria that the Committee selects for purposes of establishing the
      Performance Goal or Performance Goals for a Participant for a Performance
      Period. The Performance Criteria that will be used to establish Performance
      Goals are limited to the following: net earnings (either before or after
      interest, taxes, depreciation and amortization), net losses, sales or revenue,
      operating earnings, operating cash flow, return on net assets, return on
      stockholders’ equity, return on assets, return on capital, stockholder returns,
      gross or net profit margin, earnings per share, price per share of Stock, and
      market share, any of which may be measured either in absolute terms or as
      compared to any incremental increase or as compared to results of a peer group.
      The Committee shall, within the time prescribed by Section 162(m) of the Code,
      define in an objective fashion the manner of calculating the Performance
      Criteria it selects to use for such Performance Period for such
      Participant.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

     

    (v)  “Performance
      Goals”
means,
      for a Performance Period, the goals established in writing by the Committee
      for
      the Performance Period based upon the Performance Criteria. Depending on the
      Performance Criteria used to establish such Performance Goals, the Performance
      Goals may be expressed in terms of overall Company performance or the
      performance of a division, business unit, or an individual. The Committee,
      in
      its discretion, may, within the time prescribed by Section 162(m) of the Code,
      adjust or modify the calculation of Performance Goals for such Performance
      Period in order to prevent the dilution or enlargement of the rights of
      Participants (i) in the event of, or in anticipation of, any unusual or
      extraordinary corporate item, transaction, event, or development, or (ii) in
      recognition of, or in anticipation of, any other unusual or nonrecurring events
      affecting the Company, or the financial statements of the Company, or in
      response to, or in anticipation of, changes in applicable laws, regulations,
      accounting principles, or business conditions.

     

    (w)  “Performance
      Period”
means
      the one or more periods of time, which may be of varying and overlapping
      durations, as the Committee may select, over which the attainment of one or
      more
      Performance Goals will be measured for the purpose of determining a
      Participant’s right to, and the payment of, a Performance-Based
      Award.

     

    (x)  “Performance
      Share”
means
      a
      right granted to a Participant pursuant to Article 8, to receive cash, Stock,
      or
      other Awards, the payment of which is contingent upon achieving certain
      performance goals established by the Committee.

     

    (y)  “Plan”
means
      this Sunesis Pharmaceuticals, Inc. 2005 Equity Incentive Award Plan, as it
      may
      be amended from time to time.

     

    (z)  “Public
      Trading Date”
means
      the first date upon which Stock is listed (or approved for listing) upon notice
      of issuance on any securities exchange or designated (or approved for
      designation) upon notice of issuance as a national market security on an
      interdealer quotation system.

     

    (aa)  “Qualified
      Performance-Based Compensation”
means
      any compensation that is intended to qualify as “qualified performance-based
      compensation” as described in Section 162(m)(4)(C) of the Code.

     

    (bb)  “Restricted
      Stock”
means
      Stock awarded to a Participant pursuant to Article 6 that is subject to certain
      restrictions and to risk of forfeiture.

     

    (cc)  “Restricted
      Stock Unit”
means
      a
      right to receive a specified number of shares of Stock during specified time
      periods pursuant to Article 8.

     

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    (dd)  “Stock”
means
      the common stock of the Company and such other securities of the Company that
      may be substituted for Stock pursuant to Article 11.

     

    (ee)  “Stock
      Appreciation Right”
or
      “SAR”
means
      a
      right granted pursuant to Article 7 to receive a payment equal to the excess
      of
      the Fair Market Value of a specified number of shares of Stock on the date
      the
      SAR is exercised over the Fair Market Value on the date the SAR was granted
      as
      set forth in the applicable Award Agreement.

     

    (ff)  “Stock
      Payment”
means
      (a) a payment in the form of shares of Stock, or (b) an option or other right
      to
      purchase shares of Stock, as part of any bonus, deferred compensation or other
      arrangement, made in lieu of all or any portion of the compensation, granted
      pursuant to Article 8.

     

    (gg)  “Subsidiary”
means
      any corporation or other entity of which a majority of the outstanding voting
      stock or voting power is beneficially owned directly or indirectly by the
      Company.

     

    ARTICLE
      3

    SHARES
      SUBJECT TO THE PLAN

     

    3.1  Number
      of Shares.
      

     

    (a) Subject
      to Article 11, the aggregate number of shares of Stock which may be issued
      or
      transferred pursuant to Awards under the Plan shall be one million seven hundred
      seventy-nine thousand three hundred ninety-six (1,779,396) shares, plus the
      number of shares of Common Stock subject to each option granted under the
      Sunesis Pharmaceuticals, Inc. 1998 Stock Plan and the Sunesis Pharmaceuticals,
      Inc. 2001 Stock Plan (the “Existing
      Plans”)
      before
      the Public Trading Date that expire or are canceled without having been
      exercised in full or shares of Stock that are repurchased by the Company
      pursuant to the terms of such options. In
      addition to the foregoing, subject to Article 11, commencing on the first day
      of
      the Company’s 2006 fiscal year and on the first day of each fiscal year
      thereafter during the term of the Plan, the number of shares of Stock which
      may
      be issued or transferred pursuant to Awards under the Plan shall be increased
      by
      that number of shares of Stock equal to the least of (i) four percent (4%)
      of the Company’s outstanding shares of Stock on such date, (ii) one million
      eighty-two thousand three hundred fifty-two (1,082,352) shares of Stock or
      (iii) a lesser amount determined by the Board. Notwithstanding anything to
      the contrary herein, the maximum aggregate number of shares of Stock that may
      be
      issued or transferred pursuant to Awards under the Plan during the term of
      the
      Plan is eleven million two hundred ninety-four thousand one hundred twelve
      (11,294,112) shares, subject to Article 11. The payment of Dividend
      Equivalents in conjunction with any outstanding Awards shall not be counted
      against the shares available for issuance under the Plan.

     

    (b) To
      the
      extent that an Award terminates, expires, or lapses for any reason, any shares
      of Stock subject to the Award shall again be available for the grant of an
      Award
      pursuant to the Plan. Additionally, any shares of Stock tendered or withheld
      to
      satisfy the grant or exercise price or tax withholding obligation pursuant
      to
      any Award shall again be available for the grant of an Award pursuant to the
      Plan. To the extent permitted by applicable law or any exchange rule, shares
      of
      Stock issued in assumption of, or in substitution for, any outstanding awards
      of
      any entity acquired in any form of combination by the Company or any Subsidiary
      shall not be counted against shares of Stock available for grant pursuant to
      this Plan.

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    (c) Notwithstanding
      the provisions of this Section 3.1 no shares of Stock may again be optioned,
      granted or awarded if such action would cause an Incentive Stock Option to
      fail
      to qualify as an Incentive Stock Option under Code Section 422.

     

    3.2  Stock
      Distributed.
      Any
      Stock distributed pursuant to an Award may consist, in whole or in part, of
      authorized and unissued Stock, treasury Stock or Stock purchased on the open
      market.

     

    3.3  Limitation
      on Number of Shares Subject to Awards.
      Notwithstanding any provision in the Plan to the contrary, and subject to
      Article 11, the maximum number of shares of Stock with respect to one or more
      Awards that may be granted to any one Participant during a calendar year shall
      be two hundred thirty-five thousand two hundred ninety-four
      (235,294).

     

    ARTICLE
      4

    ELIGIBILITY
      AND PARTICIPATION

     

    4.1  Eligibility.

     

    (a)  General.
      Persons eligible to participate in this Plan include Employees, consultants
      to
      the Company or any Subsidiary and all members of the Board, as determined by
      the
      Committee. 

     

    (b)  Foreign
      Participants. In order to assure the viability of Awards granted to Participants
      employed in foreign countries, the Committee may provide for such special terms
      as it may consider necessary or appropriate to accommodate differences in local
      law, tax policy, or custom. Moreover, the Committee may approve such supplements
      to, or amendments, restatements, or alternative versions of, the Plan as it
      may
      consider necessary or appropriate for such purposes without thereby affecting
      the terms of the Plan as in effect for any other purpose; provided,
      however,
      that no
      such supplements, amendments, restatements, or alternative versions shall
      increase the share limitations contained in Sections 3.1 and 3.3 of the Plan.
      

     

    4.2  Actual
      Participation.
      Subject
      to the provisions of the Plan, the Committee may, from time to time, select
      from
      among all eligible individuals, those to whom Awards shall be granted and shall
      determine the nature and amount of each Award. No individual shall have any
      right to be granted an Award pursuant to this Plan.

     

    ARTICLE
      5

    STOCK
      OPTIONS

     

    5.1  General.
      The
      Committee is authorized to grant Options to Participants on the following terms
      and conditions:

     

    (a)  Exercise
      Price. The exercise price per share of Stock subject to an Option shall be
      determined by the Committee and set forth in the Award Agreement; provided
      that the
      exercise price for any Option shall not be less than par value of a share of
      Stock on the date of grant.

     

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

     

    (b)  Time
      And
      Conditions Of Exercise. The Committee shall determine the time or times at
      which
      an Option may be exercised in whole or in part, provided
      that the
      term of any Option granted under the Plan shall not exceed ten years, and
provided
      further,
      that in
      the case of a Non-Qualified Stock Option, such Option shall be exercisable
      for
      one year after the date of the Participant’s death, provided that this one (1)
      year period does not exceed the Option’s ten (10) year term, as described above.
      The Committee shall also determine the performance or other conditions, if
      any,
      that must be satisfied before all or part of an Option may be
      exercised.

     

    (c)  Payment.
      The Committee shall determine the methods by which the exercise price of an
      Option may be paid, the form of payment, including, without limitation, cash,
      promissory note bearing interest at no less than such rate as shall then
      preclude the imputation of interest under the Code, shares of Stock held for
      longer than six months having a Fair Market Value on the date of delivery equal
      to the aggregate exercise price of the Option or exercised portion thereof,
      or
      other property acceptable to the Committee (including through the delivery
      of a
      notice that the Participant has placed a market sell order with a broker with
      respect to shares of Stock then issuable upon exercise of the Option, and that
      the broker has been directed to pay a sufficient portion of the net proceeds
      of
      the sale to the Company in satisfaction of the Option exercise price,
provided
      that
      payment of such proceeds is then made to the Company upon settlement of such
      sale), and the methods by which shares of Stock shall be delivered or deemed
      to
      be delivered to Participants. Notwithstanding any other provision of the Plan
      to
      the contrary, no Participant who is a member of the Board or an “executive
      officer” of the Company within the meaning of Section 13(k) of the Exchange Act
      shall be permitted to pay the exercise price of an Option in any method which
      would violate Section 13(k). 

     

    (d)  Evidence
      Of Grant. All Options shall be evidenced by a written Award Agreement between
      the Company and the Participant. The Award Agreement shall include such
      additional provisions as may be specified by the Committee.

     

    5.2  Incentive
      Stock Options.
      Incentive Stock Options shall be granted only to Employees who are employed
      by
      the Company or any subsidiary corporation within the meaning of Code Section
      424(f) and the terms of any Incentive Stock Options granted pursuant to the
      Plan
      must comply with the following additional provisions of this Section
      5.2:

     

    (a)  Exercise
      Price. The exercise price per share of Stock shall be set by the Committee,
      provided
      that the
      exercise price for any Incentive Stock Option shall not be less than 100% of
      the
      Fair Market Value on the date of grant. 

     

    (b)  Expiration
      Of Option. An Incentive Stock Option may not be exercised to any extent by
      anyone after the first to occur of the following events:

     

    (1)  Ten
      years
      from the date it is granted, unless an earlier time is set in the Award
      Agreement.

     

    (2)  One
      year
      after the date of the Participant’s termination of employment or service on
      account of Disability or death, unless in the case of death a shorter or longer
      period is designated in the Award Agreement. Upon the Participant’s Disability
      or death, any Incentive Stock Options exercisable at the Participant’s
      Disability or death may be exercised by the Participant’s legal representative
      or representatives, by the person or persons entitled to do so pursuant to
      the
      Participant’s last will and testament, or, if the Participant fails to make
      testamentary disposition of such Incentive Stock Option or dies intestate,
      by
      the person or persons entitled to receive the Incentive Stock Option pursuant
      to
      the applicable laws of descent and distribution.

     

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

     

    (c)  Individual
      Dollar Limitation. The aggregate Fair Market Value (determined as of the time
      the Option is granted) of all shares of Stock with respect to which Incentive
      Stock Options are first exercisable by a Participant in any calendar year may
      not exceed $100,000.00 or such other limitation as imposed by Section 422(d)
      of
      the Code, or any successor provision. To the extent that Incentive Stock Options
      are first exercisable by a Participant in excess of such limitation, the excess
      shall be considered Non-Qualified Stock Options.

     

    (d)  Ten
      Percent Owners. An Incentive Stock Option shall be granted to any individual
      who, at the date of grant, owns stock possessing more than ten percent of the
      total combined voting power of all classes of stock of the Company (or any
      parent and subsidiary corporations, within the meaning of Code Section 424(e)
      and (f)) only if such Option is granted at a price that is not less than 110%
      of
      Fair Market Value on the date of grant and the Option is exercisable for no
      more
      than five years from the date of grant.

     

    (e)  Transfer
      Restriction. The Participant shall give the Company prompt notice of any
      disposition of shares of Stock acquired by exercise of an Incentive Stock Option
      within (1) two years from the date of grant of such Incentive Stock Option
      or
      (2) one year after the transfer of such shares of Stock to the
      Participant.

     

    (f)  Expiration
      Of Incentive Stock Options. No Award of an Incentive Stock Option may be made
      pursuant to this Plan after the Expiration Date (as defined in Section
      13.2).

     

    (g)  Right
      To
      Exercise. During a Participant’s lifetime, an Incentive Stock Option may be
      exercised only by the Participant.

     

    5.3  Granting
      Of Options To Independent Directors.
      

     

    (a)  During
      the term of the Plan, a person who first becomes a Non-Employee Director after
      the Public Trading Date automatically shall be granted an Option to purchase
      30,000 shares of Stock (an “Initial Option”). Following the Public Trading Date
      and commencing on the Company’s 2006 annual meeting of the stockholders,
      Non-Employee Directors automatically shall be granted an Option to purchase
      10,000 shares of Stock effective as of each annual meeting of the stockholders
      (an “Annual Option”); provided,
      he or
      she continues to serve as member of the Board as of such date. For the avoidance
      of doubt, an Non-Employee Director elected for the first time to the Board
      at an
      annual meeting of stockholders shall only receive an Initial Option in
      connection with such election, and shall not receive an Annual Option on the
      date following such meeting as well. Members of the Board who are employees
      of
      the Company who subsequently retire from the Company and remain on the Board
      will not receive an Initial Option grant but to the extent they are otherwise
      eligible, will receive, at each annual meeting of stockholders after his or
      her
      retirement from employment with the Company, an Annual Option grant.

     

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    (b)  Options
      granted to Non-Employee Directors shall be Non-Qualifed Stock Options. The
      per
      Share price of each Option granted to an Non-Employee Director shall equal
      100%
      of the Fair Market Value of a share of Common Stock on the date the Option
      is
      granted. Initial Options shall become vested and exercisable in two (2) equal
      annual installments over the two (2) year period commencing with the date of
      grant. Annual Options shall become vested and exercisable in twelve (12) equal
      monthly installments over the twelve (12) month period following their date
      of
      grant. The term of each Option granted to an Non-Employee Director shall be
      ten
      (10) years from the date the Option is granted. Upon a Director’s termination of
      membership on the Board for any reason, his or her Option granted under Section
      5.3(a) shall remain exercisable for twelve (12) months following his or her
      termination of membership on the Board (or such longer period as the Board
      may
      determine in its discretion on or after the date of grant of such Option).
      Unless otherwise determined by the Board on or after the date of grant of such
      Option, no portion of an Option granted under Section 5.3(a) which is
      unexercisable at the time of an Non-Employee Director’s termination of
      membership on the Board shall thereafter become exercisable.

     

    ARTICLE
      6

    RESTRICTED
      STOCK AWARDS

     

    6.1  Grant
      of Restricted Stock.
      The
      Committee is authorized to make Awards of Restricted Stock to any Participant
      selected by the Committee in such amounts and subject to such terms and
      conditions as determined by the Committee. All Awards of Restricted Stock shall
      be evidenced by a written Restricted Stock Award Agreement. 

     

    6.2  Issuance
      and Restrictions.
      Restricted Stock shall be subject to such restrictions on transferability and
      other restrictions as the Committee may impose (including, without limitation,
      limitations on the right to vote Restricted Stock or the right to receive
      dividends on the Restricted Stock). These restrictions may lapse separately
      or
      in combination at such times, pursuant to such circumstances, in such
      installments, or otherwise, as the Committee determines at the time of the
      grant
      of the Award or thereafter. 

     

    6.3  Forfeiture.
      Except
      as otherwise determined by the Committee at the time of the grant of the Award
      or thereafter, upon termination of employment or service during the applicable
      restriction period, Restricted Stock that is at that time subject to
      restrictions shall be forfeited; provided,
      however,
      that
      the Committee may provide in any Restricted Stock Award Agreement that
      restrictions or forfeiture conditions relating to Restricted Stock will be
      waived in whole or in part in the event of terminations resulting from specified
      causes, and the Committee may in other cases waive in whole or in part
      restrictions or forfeiture conditions relating to Restricted Stock.

     

    6.4  Certificates
      For Restricted Stock.
      Restricted Stock granted pursuant to the Plan may be evidenced in such manner
      as
      the Committee shall determine. If certificates representing shares of Restricted
      Stock are registered in the name of the Participant, certificates must bear
      an
      appropriate legend referring to the terms, conditions, and restrictions
      applicable to such Restricted Stock, and the Company may, at its discretion,
      retain physical possession of the certificate until such time as all applicable
      restrictions lapse.

     

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    ARTICLE
      7

    STOCK
      APPRECIATION RIGHTS

     

    7.1 Grant
      of Stock Appreciation Rights. A
      Stock
      Appreciation Right may be granted to any Participant selected by the Committee.
      A Stock Appreciation Right may be granted (a) in connection and
      simultaneously with the grant of an Option, (b) with respect to a
      previously granted Option, or (c) independent of an Option. A Stock
      Appreciation Right shall be subject to such terms and conditions not
      inconsistent with the Plan as the Committee shall impose and shall be evidenced
      by an Award Agreement.

     

    7.2 Coupled
      Stock Appreciation Rights.

     

    (a) A
      Coupled
      Stock Appreciation Right (“CSAR”)
      shall
      be related to a particular Option and shall be exercisable only when and to
      the
      extent the related Option is exercisable.

     

    (b) A
      CSAR
      may be granted to a Participant for no more than the number of shares subject
      to
      the simultaneously or previously granted Option to which it is
      coupled.

     

    (c) A
      CSAR
      shall entitle the Participant (or other person entitled to exercise the Option
      pursuant to the Plan) to surrender to the Company unexercised a portion of
      the
      Option to which the CSAR relates (to the extent then exercisable pursuant to
      its
      terms) and to receive from the Company in exchange therefor an amount determined
      by multiplying the difference obtained by subtracting the Option exercise price
      from the Fair Market Value of a share of Stock on the date of exercise of the
      CSAR by the number of shares of Stock with respect to which the CSAR shall
      have
      been exercised, subject to any limitations the Committee may
      impose.

     

    7.3 Independent
      Stock Appreciation Rights.

     

    (a) An
      Independent Stock Appreciation Right (“ISAR”)
      shall
      be unrelated to any Option and shall have a term set by the Committee. An ISAR
      shall be exercisable in such installments as the Committee may determine. An
      ISAR shall cover such number of shares of Stock as the Committee may determine.
      The exercise price per share of Stock subject to each ISAR shall be set by
      the
      Committee; provided,
      however,
      that,
      the Committee in its sole and absolute discretion may provide that the ISAR
      may
      be exercised subsequent to a termination of employment or service, as
      applicable, or following a Change of Control of the Company, or because of
      the
      Participant’s retirement, death or disability, or otherwise.

     

    (b) An
      ISAR
      shall entitle the Participant (or other person entitled to exercise the ISAR
      pursuant to the Plan) to exercise all or a specified portion of the ISAR (to
      the
      extent then exercisable pursuant to its terms) and to receive from the Company
      an amount determined by multiplying the difference obtained by subtracting
      the
      exercise price per share of the ISAR from the Fair Market Value of a share
      of
      Stock on the date of exercise of the ISAR by the number of shares of Stock
      with
      respect to which the ISAR shall have been exercised, subject to any limitations
      the Committee may impose.

     

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

     

    7.4 Payment
      and Limitations on Exercise.

     

    (a) Payment
      of the amounts determined under Section 7.2(c) and 7.3(b) above shall be in
      cash, in Stock (based on its Fair Market Value as of the date the Stock
      Appreciation Right is exercised) or a combination of both, as determined by
      the
      Committee. 

     

    (b) To
      the
      extent any payment under Section 7.2(c) or 7.3(b) is effected in Stock it shall
      be made subject to satisfaction of all provisions of Article 5 above pertaining
      to Options.

    

    ARTICLE
      8

    OTHER
      TYPES OF AWARDS

     

    8.1 Performance
      Share Awards. Any
      Participant selected by the Committee may be granted one or more Performance
      Share awards which may be denominated in a number of shares of Stock or in
      a
      dollar value of shares of Stock and which may be linked to any one or more
      of
      the Performance Criteria or other specific performance criteria determined
      appropriate by the Committee, in each case on a specified date or dates or
      over
      any period or periods determined by the Committee. In making such
      determinations, the Committee shall consider (among such other factors as it
      deems relevant in light of the specific type of award) the contributions,
      responsibilities and other compensation of the particular Participant.

     

    8.2 Dividend
      Equivalents. 

     

    (a) Any
      Participant selected by the Committee may be granted Dividend Equivalents based
      on the dividends declared on the shares of Stock that are subject to any Award,
      to be credited as of dividend payment dates, during the period between the
      date
      the Award is granted and the date the Award is exercised, vests or expires,
      as
      determined by the Committee. Such Dividend Equivalents shall be converted to
      cash or additional shares of Stock by such formula and at such time and subject
      to such limitations as may be determined by the Committee.

     

    (b) Dividend
      Equivalents granted with respect to Options or SARs that are intended to be
      Qualified Performance-Based Compensation shall be payable, with respect to
      pre-exercise periods, regardless of whether such Option or SAR is subsequently
      exercised.

     

    8.3 Stock
      Payments. 

     

    Any
      Participant selected by the Committee may receive Stock Payments in the manner
      determined from time to time by the Committee. The number of shares shall be
      determined by the Committee and may be based upon the Performance Criteria
      or
      other specific performance criteria determined appropriate by the Committee,
      determined on the date such Stock Payment is made or on any date
      thereafter.

     

    
      
         

      

      
        12

        
          

        

      

      
         

      

    

     

    8.4 Restricted
      Stock Units. 

     

    Any
      Participant selected by the Committee may be granted an award of Restricted
      Stock Units in the manner determined from time to time by the Committee. The
      number of Restricted Stock Units shall be determined by the Committee and may
      be
      linked to the Performance Criteria or other specific performance criteria
      determined to be appropriate by the Committee, in each case on a specified
      date
      or dates or over any period or periods determined by the Committee. Stock
      underlying a Restricted Stock Unit award will not be issued until the Restricted
      Stock Unit award has vested, pursuant to a vesting schedule or performance
      criteria set by the Committee. Unless otherwise provided by the Committee,
      a
      Participant awarded Restricted Stock Units shall have no rights as a Company
      stockholder with respect to such Restricted Stock Units until such time as
      the
      Restricted Stock Units have vested and the Stock underlying the Restricted
      Stock
      Units has been issued.

     

    8.5 Term. 

     

    The
      term
      of any Award of Performance Shares, Dividend Equivalents, Stock Payments or
      Restricted Stock Units shall be set by the Committee in its
      discretion.

     

    8.6 Exercise
      or Purchase Price. 

     

    The
      Committee may establish the exercise or purchase price of any Award of
      Performance Shares, Restricted Stock Units or Stock Payments; provided,
      however,
      that
      such price shall not be less than the par value of a share of Stock, unless
      otherwise permitted by applicable state law.

     

    8.7 Exercise
      Upon Termination of Employment or Service. An
      Award
      of Performance Shares, Dividend Equivalents, Restricted Stock Units and Stock
      Payments shall only be exercisable or payable while the Participant is an
      Employee, consultant to the Company or a member of the Board, as applicable;
      provided, however, that the Committee in its sole and absolute discretion may
      provide that an Award of Performance Shares, Dividend Equivalents, Stock
      Payments or Restricted Stock Units may be exercised or paid subsequent to a
      termination of employment or service, as applicable, or following a Change
      of
      Control of the Company, or because of the Participant’s retirement, death or
      disability, or otherwise; provided, however, that any such provision with
      respect to Performance Shares shall be subject to the requirements of Section
      162(m) of the Code that apply to Qualified Performance-Based
      Compensation.

     

    8.8 Form
      of Payment. 

     

    Payments
      with respect to any Awards granted under this Article 8 shall be made in cash,
      in Stock or a combination of both, as determined by the Committee. 

     

    8.9 Award
      Agreement.
      All
      Awards under this Article 8 shall be subject to such additional terms and
      conditions as determined by the Committee and shall be evidenced by a written
      Award Agreement.

     

    ARTICLE
      9

    PERFORMANCE-BASED
      AWARDS

     

    9.1  Purpose.
      The
      purpose of this Article 9 is to provide the Committee the ability to qualify
      Awards other than Options and SARs and that are granted pursuant to Articles
      6
      and 8 as Qualified Performance-Based Compensation. If the Committee, in its
      discretion, decides to grant a Performance-Based Award to a Covered Employee,
      the provisions of this Article 9 shall control over any contrary provision
      contained in Articles 6 or 8; provided,
      however,
      that
      the Committee may in its discretion grant Awards to Covered Employees that
      are
      based on Performance Criteria or Performance Goals but that do not satisfy
      the
      requirements of this Article 9. 

     

    
      
         

      

      
        13

        
          

        

      

      
         

      

    

     

    9.2  Applicability.
      This
      Article 9 shall apply only to those Covered Employees selected by the Committee
      to receive Performance-Based Awards. The designation of a Covered Employee
      as a
      Participant for a Performance Period shall not in any manner entitle the
      Participant to receive an Award for the period. Moreover, designation of a
      Covered Employee as a Participant for a particular Performance Period shall
      not
      require designation of such Covered Employee as a Participant in any subsequent
      Performance Period and designation of one Covered Employee as a Participant
      shall not require designation of any other Covered Employees as a Participant
      in
      such period or in any other period.

     

    9.3  Procedures
      With Respect to Performance-Based Awards.
      To the
      extent necessary to comply with the Qualified Performance-Based Compensation
      requirements of Section 162(m)(4)(C) of the Code, with respect to any Award
      granted under Articles 6 and 8 which may be granted to one or more Covered
      Employees, no later than ninety (90) days following the commencement of any
      fiscal year in question or any other designated fiscal period or period of
      service (or such other time as may be required or permitted by Section 162(m)
      of
      the Code), the Committee shall, in writing, (i) designate one or more Covered
      Employees, (ii) select the Performance Criteria applicable to the Performance
      Period, (iii) establish the Performance Goals, and amounts of such Awards,
      as
      applicable, which may be earned for such Performance Period, and (iv) specify
      the relationship between Performance Criteria and the Performance Goals and
      the
      amounts of such Awards, as applicable, to be earned by each Covered Employee
      for
      such Performance Period. Following the completion of each Performance Period,
      the Committee shall certify in writing whether the applicable Performance Goals
      have been achieved for such Performance Period. In determining the amount earned
      by a Covered Employee, the Committee shall have the right to reduce or eliminate
      (but not to increase) the amount payable at a given level of performance to
      take
      into account additional factors that the Committee may deem relevant to the
      assessment of individual or corporate performance for the Performance
      Period.

     

    9.4  Payment
      of Performance-Based Awards.
      Unless
      otherwise provided in the applicable Award Agreement, a Participant must be
      employed by the Company or a Subsidiary on the day a Performance-Based Award
      for
      such Performance Period is paid to the Participant. Furthermore, a Participant
      shall be eligible to receive payment pursuant to a Performance-Based Award
      for a
      Performance Period only if the Performance Goals for such period are achieved.
      In determining the amount earned under a Performance-Based Award, the Committee
      may reduce or eliminate the amount of the Performance-Based Award earned for
      the
      Performance Period, if in its sole and absolute discretion, such reduction
      or
      elimination is appropriate.

     

    9.5  Additional
      Limitations.
      Notwithstanding any other provision of the Plan, any Award which is granted
      to a
      Covered Employee and is intended to constitute Qualified Performance-Based
      Compensation shall be subject to any additional limitations set forth in Section
      162(m) of the Code (including any amendment to Section 162(m) of the Code)
      or
      any regulations or rulings issued thereunder that are requirements for
      qualification as qualified performance-based compensation as described in
      Section 162(m)(4)(C) of the Code, and the Plan shall be deemed amended to the
      extent necessary to conform to such requirements.

     

    
      
         

      

      
        14

        
          

        

      

      
         

      

    

     

    ARTICLE
      10

    PROVISIONS
      APPLICABLE TO AWARDS

     

    10.1  Stand-Alone
      and Tandem Awards.
      Awards
      granted pursuant to the Plan may, in the discretion of the Committee, be granted
      either alone, in addition to, or in tandem with, any other Award granted
      pursuant to the Plan. Awards granted in addition to or in tandem with other
      Awards may be granted either at the same time as or at a different time from
      the
      grant of such other Awards.

     

    10.2  Award
      Agreement.
      Awards
      under the Plan shall be evidenced by Award Agreements that set forth the terms,
      conditions and limitations for each Award which may include the term of an
      Award, the provisions applicable in the event the Participant’s employment or
      service terminates, and the Company’s authority to unilaterally or bilaterally
      amend, modify, suspend, cancel or rescind an Award.

     

    10.3  Limits
      on Transfer.
      No
      right or interest of a Participant in any Award may be pledged, encumbered,
      or
      hypothecated to or in favor of any party other than the Company or a Subsidiary,
      or shall be subject to any lien, obligation, or liability of such Participant
      to
      any other party other than the Company or a Subsidiary. Except as otherwise
      provided by the Committee, no Award shall be assigned, transferred, or otherwise
      disposed of by a Participant other than by will or the laws of descent and
      distribution. The Committee by express provision in the Award or an amendment
      thereto may permit an Award (other than an Incentive Stock Option) to be
      transferred to, exercised by and paid to certain persons or entities related to
      the Participant, including but not limited to members of the Participant’s
      family, charitable institutions, or trusts or other entities whose beneficiaries
      or beneficial owners are members of the Participant’s family and/or charitable
      institutions, or to such other persons or entities as may be expressly approved
      by the Committee, pursuant to such conditions and procedures as the Committee
      may establish. Any permitted transfer may be subject to the condition that
      the
      Committee receive evidence satisfactory to it that the transfer is being made
      for estate and/or tax planning purposes (or to a “blind trust” in connection
      with the Participant’s termination of employment or service with the Company or
      a Subsidiary to assume a position with a governmental, charitable, educational
      or similar non-profit institution) and on a basis consistent with the Company’s
      lawful issue of securities.

     

    10.4  Beneficiaries.
      Notwithstanding Section 10.3, a Participant may, in the manner determined by
      the
      Committee, designate a beneficiary to exercise the rights of the Participant
      and
      to receive any distribution with respect to any Award upon the Participant’s
      death. A beneficiary, legal guardian, legal representative, or other person
      claiming any rights pursuant to the Plan is subject to all terms and conditions
      of the Plan and any Award Agreement applicable to the Participant, except to
      the
      extent the Plan and Award Agreement otherwise provide, and to any additional
      restrictions deemed necessary or appropriate by the Committee. If the
      Participant is married and resides in a community property state, a designation
      of a person other than the Participant’s spouse as his beneficiary with respect
      to more than 50% of the Participant’s interest in the Award shall not be
      effective without the prior written consent of the Participant’s spouse. If no
      beneficiary has been designated or survives the Participant, payment shall
      be
      made to the person entitled thereto pursuant to the Participant’s will or the
      laws of descent and distribution. Subject to the foregoing, a beneficiary
      designation may be changed or revoked by a Participant at any time provided
      the
      change or revocation is filed with the Committee. 

     

    
      
         

      

      
        15

        
          

        

      

      
         

      

    

     

    10.5  Stock
      Certificates.
      Notwithstanding anything herein to the contrary, the Company shall not be
      required to issue or deliver any certificates evidencing shares of Stock
      pursuant to the exercise of any Award, unless and until the Board has
      determined, with advice of counsel, that the issuance and delivery of such
      certificates is in compliance with all applicable laws, regulations of
      governmental authorities and, if applicable, the requirements of any exchange
      on
      which the shares of Stock are listed or traded. All Stock certificates delivered
      pursuant to the Plan are subject to any stop-transfer orders and other
      restrictions as the Committee deems necessary or advisable to comply with
      federal, state, or foreign jurisdiction, securities or other laws, rules and
      regulations and the rules of any national securities exchange or automated
      quotation system on which the Stock is listed, quoted, or traded. The Committee
      may place legends on any Stock certificate to reference restrictions applicable
      to the Stock. In addition to the terms and conditions provided herein, the
      Board
      may require that a Participant make such reasonable covenants, agreements,
      and
      representations as the Board, in its discretion, deems advisable in order to
      comply with any such laws, regulations, or requirements. The Committee shall
      have the right to require any Participant to comply with any timing or other
      restrictions with respect to the settlement or exercise of any Award, including
      a window-period limitation, as may be imposed in the discretion of the
      Committee. 

     

    ARTICLE
      11

    CHANGES
      IN CAPITAL STRUCTURE

     

    11.1  Adjustments.
      In the
      event of any stock dividend, stock split, combination or exchange of shares,
      merger, consolidation, spin-off, recapitalization or other distribution (other
      than normal cash dividends) of Company assets to stockholders, or any other
      change affecting the shares of Stock or the share price of the Stock, the
      Committee shall make such proportionate adjustments, if any, as the Committee
      in
      its discretion may deem appropriate to reflect such change with respect to
      (i)
      the aggregate number and type of shares that may be issued under the Plan
      (including, but not limited to, adjustments of the limitations in Sections
      3.1
      and 3.3); (ii) the terms and conditions of any outstanding Awards (including,
      without limitation, any applicable performance targets or criteria with respect
      thereto); and (iii) the grant or exercise price per share for any outstanding
      Awards under the Plan. Any adjustment affecting an Award intended as Qualified
      Performance-Based Compensation shall be made consistent with the requirements
      of
      Section 162(m) of the Code.

     

    11.2  Effect
      of a Change of Control When Awards Are Not Assumed.
      If a
      Change of Control occurs and a Participant’s Awards are not assumed by the
      surviving or successor entity or its parent or Subsidiary and such successor
      does not substitute substantially similar awards for those outstanding under
      the
      Plan, such Awards shall become fully exercisable and/or payable as applicable,
      and all forfeiture restrictions on such Awards shall lapse. Upon, or in
      anticipation of, a Change of Control, the Committee may cause any and all Awards
      outstanding hereunder to terminate at a specific time in the future and shall
      give each Participant the right to exercise such Awards during a period of
      time
      as the Committee, in its sole and absolute discretion, shall determine. The
      Committee shall have sole discretion to determine whether an Award has been
      assumed by the surviving or successor entity or its parent or Subsidiary or
      whether such successor has substituted substantially similar awards for those
      outstanding under the Plan in connection with a Change of Control.

     

    
      
         

      

      
        16

        
          

        

      

      
         

      

    

     

    11.3  Effect
      of Change of Control When Awards Are Assumed; Termination Following Change
      of
      Control.
      

     

    (a) In
      the
      event of a Change of Control where a Participant’s Awards are assumed by the
      surviving or successor entity or its parent or Subsidiary or such successor
      substitutes substantially similar awards for those outstanding under the Plan,
      then fifty percent (50%) of such Participant’s unvested Awards shall become
      fully exercisable and/or payable as applicable, and all forfeiture restrictions
      on such Awards shall lapse, immediately prior to such Change of Control.

     

    (b) In
      the
      event of a Change of Control where a Participant’s Awards are assumed by the
      surviving or successor entity or its parent or Subsidiary or such successor
      substitutes substantially similar awards for those outstanding under the Plan,
      if within twelve (12) months following such Change of Control (i) the
      Participant’s employment or service with the surviving or successor entity or
      its parent or Subsidiary is terminated without Cause or (ii) such Participant
      voluntarily terminates such Participant’s employment or service with Good
      Reason, then such Participant’s remaining unvested Awards (including any
      substituted awards) shall become fully exercisable and/or payable as applicable,
      and all forfeiture restrictions on such Awards (including any substituted
      awards) shall lapse, on the date of termination. Such Awards (including any
      substituted awards) shall remain exercisable, as applicable, until the earlier
      of the expiration date of the Award or three (3) months following such
      Participant’s cessation of employment or service.

     

    11.4  Outstanding
      Awards - Certain Mergers.
      Subject
      to any required action by the stockholders of the Company, in the event that
      the
      Company shall be the surviving corporation in any merger or consolidation
      (except a merger or consolidation as a result of which the holders of shares
      of
      Stock receive securities of another corporation), each Award outstanding on
      the
      date of such merger or consolidation shall pertain to and apply to the
      securities that a holder of the number of shares of Stock subject to such Award
      would have received in such merger or consolidation.

     

    11.5  Outstanding
      Awards - Other Changes.
      In the
      event of any other change in the capitalization of the Company or corporate
      change other than those specifically referred to in this Article 11, the
      Committee may, in its absolute discretion, make such adjustments in the number
      and class of shares subject to Awards outstanding on the date on which such
      change occurs and in the per share grant or exercise price of each Award as
      the
      Committee may consider appropriate to prevent dilution or enlargement of
      rights.

     

    11.6  No
      Other Rights.
      Except
      as expressly provided in the Plan, no Participant shall have any rights by
      reason of any subdivision or consolidation of shares of stock of any class,
      the
      payment of any dividend, any increase or decrease in the number of shares of
      stock of any class or any dissolution, liquidation, merger, or consolidation
      of
      the Company or any other corporation. Except as expressly provided in the Plan
      or pursuant to action of the Committee under the Plan, no issuance by the
      Company of shares of stock of any class, or securities convertible into shares
      of stock of any class, shall affect, and no adjustment by reason thereof shall
      be made with respect to, the number of shares of Stock subject to an Award
      or
      the grant or exercise price of any Award.

     

    
      
         

      

      
        17

        
          

        

      

      
         

      

    

     

    ARTICLE
      12

    ADMINISTRATION

     

    12.1  Committee.
      Unless
      and until the Board delegates administration to a Committee as set forth below,
      the Plan shall be administered by the Board. The Board may delegate
      administration of the Plan to a Committee or Committees of one or more members
      of the Board, and the term “Committee” shall apply to any person or persons to
      whom such authority has been delegated. If administration is delegated to a
      Committee, the Committee shall have, in connection with the administration
      of
      the Plan, the powers theretofore possessed by the Board, including the power
      to
      delegate to a subcommittee any of the administrative powers the Committee is
      authorized to exercise (and references in this Plan to the Board shall
      thereafter be to the Committee or subcommittee), subject, however, to such
      resolutions, not inconsistent with the provisions of the Plan, as may be adopted
      from time to time by the Board. Notwithstanding the foregoing, however, from
      and
      after the Public Trading Date, a Committee of the Board shall administer the
      Plan and the Committee shall consist solely of two or more members of the Board
      each of whom is both an “outside director,” within the meaning of Section 162(m)
      of the Code, and a Non-Employee Director. Within the scope of such authority,
      the Board or the Committee may (i) delegate to a committee of one or more
      members of the Board who are not “outside directors,” within the meaning of
      Section 162(m) of the Code the authority to grant awards under the Plan to
      eligible persons who are either (1) not then “covered employees,” within the
      meaning of Section 162(m) of the Code and are not expected to be “covered
      employees” at the time of recognition of income resulting from such award or (2)
      not persons with respect to whom the Company wishes to comply with Section
      162(m) of the Code and/or (ii) delegate to a committee of one or more members
      of
      the Board who are not Non-Employee Directors, the authority to grant awards
      under the Plan to eligible persons who are not then subject to Section 16 of
      the
      Exchange Act. The Board may abolish the Committee at any time and/or revest
      in
      the Board the administration of the Plan. Appointment of Committee members
      shall
      be effective upon acceptance of appointment. Committee members may resign at
      any
      time by delivering written notice to the Board. Vacancies in the Committee
      may
      only be filled by the Board.

     

    12.2  Action
      by the Committee.
      A
      majority of the Committee shall constitute a quorum. The acts of a majority
      of
      the members present at any meeting at which a quorum is present, and acts
      approved in writing by a majority of the Committee in lieu of a meeting, shall
      be deemed the acts of the Committee. Each member of the Committee is entitled
      to, in good faith, rely or act upon any report or other information furnished
      to
      that member by any officer or other employee of the Company or any Subsidiary,
      the Company’s independent certified public accountants, or any executive
      compensation consultant or other professional retained by the Company to assist
      in the administration of the Plan.

     

    12.3  Authority
      of Committee.
      Subject
      to any specific designation in the Plan, the Committee has the exclusive power,
      authority and discretion to:

     

    (a)  Designate
      Participants to receive Awards;

     

    
      
         

      

      
        18

        
          

        

      

      
         

      

    

     

    (b)  Determine
      the type or types of Awards to be granted to each Participant;

     

    (c)  Determine
      the number of Awards to be granted and the number of shares of Stock to which
      an
      Award will relate;

     

    (d)  Determine
      the terms and conditions of any Award granted pursuant to the Plan, including,
      but not limited to, the exercise price, grant price, or purchase price, any
      reload provision, any restrictions or limitations on the Award, any schedule
      for
      lapse of forfeiture restrictions or restrictions on the exercisability of an
      Award, and accelerations or waivers thereof, any provisions related to
      non-competition and recapture of gain on an Award, based in each case on such
      considerations as the Committee in its sole discretion determines; provided,
      however,
      that
      the Committee shall not have the authority to accelerate the vesting or waive
      the forfeiture of any Performance-Based Awards;

     

    (e)  Determine
      whether, to what extent, and pursuant to what circumstances an Award may be
      settled in, or the exercise price of an Award may be paid in, cash, Stock,
      other
      Awards, or other property, or an Award may be canceled, forfeited, or
      surrendered;

     

    (f)  Prescribe
      the form of each Award Agreement, which need not be identical for each
      Participant;

     

    (g)  Decide
      all other matters that must be determined in connection with an
      Award;

     

    (h)  Establish,
      adopt, or revise any rules and regulations as it may deem necessary or advisable
      to administer the Plan; 

     

    (i)  Interpret
      the terms of, and any matter arising pursuant to, the Plan or any Award
      Agreement; and

     

    (j)  Make
      all
      other decisions and determinations that may be required pursuant to the Plan
      or
      as the Committee deems necessary or advisable to administer the
      Plan.

     

    12.4 Decisions
      Binding.
      The
      Committee’s interpretation of the Plan, any Awards granted pursuant to the Plan,
      any Award Agreement and all decisions and determinations by the Committee with
      respect to the Plan are final, binding, and conclusive on all
      parties.

     

    ARTICLE
      13

    EFFECTIVE
      AND EXPIRATION DATE

     

    13.1  Effective
      Date.
      The
      Plan is effective as the Public Trading Date; provided
      that the
      Plan has been approved by the Company’s stockholders prior to such date.

     

    13.2  Expiration
      Date.
      The
      Plan will expire on, and no Award may be granted pursuant to the Plan after,
      the
      earlier of the tenth anniversary of (i) the date this Plan is approved by the
      Company’s stockholders or (ii) the date this Plan is approved by the Board (the
“Expiration
      Date”).
      Any
      Awards that are outstanding on the Expiration Date shall remain in force
      according to the terms of the Plan and the applicable Award Agreement. Each
      Award Agreement shall provide that it will expire on the tenth anniversary
      of
      the date of grant of the Award to which it relates.

     

    
      
         

      

      
        19

        
          

        

      

      
         

      

    

     

    ARTICLE
      14

    AMENDMENT,
      MODIFICATION, AND TERMINATION

     

    14.1  Amendment,
      Modification, and Termination.
      With
      the approval of the Board, at any time and from time to time, the Committee
      may
      terminate, amend or modify the Plan; provided,
      however,
      that
      (i) to the extent necessary and desirable to comply with any applicable law,
      regulation, or stock exchange rule, the Company shall obtain stockholder
      approval of any Plan amendment in such a manner and to such a degree as
      required, and (ii) shareholder approval is required for any amendment to the
      Plan that (A) increases the number of shares available under the Plan (other
      than any adjustment as provided by Article 11), (B) permits the Committee to
      grant Options with an exercise price that is below Fair Market Value on the
      date
      of grant, or (C) permits the Committee to extend the exercise period for an
      Option beyond ten years from the date of grant. 

     

    14.2  Awards
      Previously Granted.
      No
      termination, amendment, or modification of the Plan shall adversely affect
      in
      any material way any Award previously granted pursuant to the Plan without
      the
      prior written consent of the Participant. 

     

    ARTICLE
      15

    GENERAL
      PROVISIONS

     

    15.1  No
      Rights to Awards.
      No
      Participant, employee, or other person shall have any claim to be granted any
      Award pursuant to the Plan, and neither the Company nor the Committee is
      obligated to treat Participants, employees, and other persons
      uniformly.

     

    15.2  No
      Stockholders Rights.
      No
      Award gives the Participant any of the rights of a stockholder of the Company
      unless and until shares of Stock are in fact issued to such person in connection
      with such Award.

     

    15.3  Withholding.
      The
      Company or any Subsidiary shall have the authority and the right to deduct
      or
      withhold, or require a Participant to remit to the Company, an amount sufficient
      to satisfy federal, state, local and foreign taxes (including the Participant’s
      FICA obligation) required by law to be withheld with respect to any taxable
      event concerning a Participant arising as a result of this Plan. The Committee
      may in its discretion and in satisfaction of the foregoing requirement allow
      a
      Participant to elect to have the Company withhold shares of Stock otherwise
      issuable under an Award (or allow the return of shares of Stock) having a Fair
      Market Value equal to the sums required to be withheld. Notwithstanding any
      other provision of the Plan, the number of shares of Stock which may be withheld
      with respect to the issuance, vesting, exercise or payment of any Award (or
      which may be repurchased from the Participant of such Award within six months
      after such shares of Stock were acquired by the Participant from the Company)
      in
      order to satisfy the Participant’s federal, state, local and foreign income and
      payroll tax liabilities with respect to the issuance, vesting, exercise or
      payment of the Award shall be limited to the number of shares which have a
      Fair
      Market Value on the date of withholding or repurchase equal to the aggregate
      amount of such liabilities based on the minimum statutory withholding rates
      for
      federal, state, local and foreign income tax and payroll tax purposes that
      are
      applicable to such supplemental taxable income.

     

    
      
         

      

      
        20

        
          

        

      

      
         

      

    

     

    15.4  No
      Right to Employment or Services.
      Nothing
      in the Plan or any Award Agreement shall interfere with or limit in any way
      the
      right of the Company or any Subsidiary to terminate any Participant’s employment
      or services at any time, nor confer upon any Participant any right to continue
      in the employ or service of the Company or any Subsidiary.

     

    15.5  Unfunded
      Status of Awards.
      The
      Plan is intended to be an “unfunded” plan for incentive compensation. With
      respect to any payments not yet made to a Participant pursuant to an Award,
      nothing contained in the Plan or any Award Agreement shall give the Participant
      any rights that are greater than those of a general creditor of the Company
      or
      any Subsidiary.

     

    15.6  Indemnification.
      To the
      extent allowable pursuant to applicable law, each member of the Committee or
      of
      the Board shall be indemnified and held harmless by the Company from any loss,
      cost, liability, or expense that may be imposed upon or reasonably incurred
      by
      such member in connection with or resulting from any claim, action, suit, or
      proceeding to which he or she may be a party or in which he or she may be
      involved by reason of any action or failure to act pursuant to the Plan and
      against and from any and all amounts paid by him or her in satisfaction of
      judgment in such action, suit, or proceeding against him or her, provided
      he or
      she gives the Company an opportunity, at its own expense, to handle and defend
      the same before he or she undertakes to handle and defend it on his or her
      own
      behalf. The foregoing right of indemnification shall not be exclusive of any
      other rights of indemnification to which such persons may be entitled pursuant
      to the Company’s Certificate of Incorporation or Bylaws, as a matter of law, or
      otherwise, or any power that the Company may have to indemnify them or hold
      them
      harmless.

     

    15.7  Relationship
      to Other Benefits.
      No
      payment pursuant to the Plan shall be taken into account in determining any
      benefits pursuant to any pension, retirement, savings, profit sharing, group
      insurance, welfare or other benefit plan of the Company or any Subsidiary except
      to the extent otherwise expressly provided in writing in such other plan or
      an
      agreement thereunder.

     

    15.8  Expenses.
      The
      expenses of administering the Plan shall be borne by the Company and its
      Subsidiaries.

     

    15.9  Titles
      and Headings.
      The
      titles and headings of the Sections in the Plan are for convenience of reference
      only and, in the event of any conflict, the text of the Plan, rather than such
      titles or headings, shall control.

     

    15.10  Fractional
      Shares.
      No
      fractional shares of Stock shall be issued and the Committee shall determine,
      in
      its discretion, whether cash shall be given in lieu of fractional shares or
      whether such fractional shares shall be eliminated by rounding up or down as
      appropriate.

     

    15.11  Limitations
      Applicable to Section 16 Persons.
      Notwithstanding any other provision of the Plan, the Plan, and any Award granted
      or awarded to any Participant who is then subject to Section 16 of the Exchange
      Act, shall be subject to any additional limitations set forth in any applicable
      exemptive rule under Section 16 of the Exchange Act (including any amendment
      to
      Rule 16b-3 of the Exchange Act) that are requirements for the application of
      such exemptive rule. To the extent permitted by applicable law, the Plan and
      Awards granted or awarded hereunder shall be deemed amended to the extent
      necessary to conform to such applicable exemptive rule.

     

    
      
         

      

      
        21

        
          

        

      

      
         

      

    

     

    15.12  Government
      And Other Regulations.
      The
      obligation of the Company to make payment of awards in Stock or otherwise shall
      be subject to all applicable laws, rules, and regulations, and to such approvals
      by government agencies as may be required. The Company shall be under no
      obligation to register pursuant to the Securities Act of 1933, as amended,
      any
      of the shares of Stock paid pursuant to the Plan. If the shares paid pursuant
      to
      the Plan may in certain circumstances be exempt from registration pursuant
      to
      the Securities Act of 1933, as amended, the Company may restrict the transfer
      of
      such shares in such manner as it deems advisable to ensure the availability
      of
      any such exemption.

     

    15.13  Governing
      Law.
      The
      Plan and all Award Agreements shall be construed in accordance with and governed
      by the laws of the State of Delaware.

     

    
      
         

      

      
        22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]